Clinical Trials

SL-279252 PD1-Fc-OX40L


Overview

Shattuck Labs’ global Phase 1 clinical trial with its lead compound, SL-279252, commenced in 2019 and dose escalation is expected to be completed in 2020. This study includes two dose expansion cohorts: one that will enroll patients with non-small cell lung cancer and another “all comers” cohort. This molecule is being developed in a partnership with Takeda Pharmaceuticals.

SL-279252 Clinical Trial Locations


United States, Tennessee
  • Nashville, Tennessee, United States, 37203, Recruiting
United States, Texas
  • Houston, Texas, United States, 77030 – Recruiting
Belgium
  • Leuven, Belgium, 3000 – Recruiting
Canada, Ontario
  • Toronto, Ontario, Canada, M5G 1Z5 – Recruiting
Spain
  • Barcelona, Spain, 08035 – Recruiting

Healthcare Professionals: To learn more about Shattuck’s trials, email clinicaltrials@shattucklabs.com.

Patients and Caregivers: Talk to your doctor if you are interested in learning more about Shattuck clinical trials.

Investigational: These molecules and their uses are investigational and have not been approved for use anywhere in the world.